CompletedNot Applicable

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

United States30 participantsStarted 2013-08

Plain-language summary

Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when admitted to medical/surgical units. During the last 15 months, the investigators have implemented a benzodiazepine-sparing management approach with very positive clinical outcomes. The BZDP-sparing protocol consists of a combination of alpha-2 agonist and/or anticonvulsant agents; all currently being used for the management of other medical conditions. This project intends to collect and analyze the data of all subjects managed with this approach to better understand its effectiveness and assess for potential adverse effects.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All the cases referred to the Psychosomatic Medicine Service for assistance with prophylactic or symptomatic management of AWS starting 8/1/2011 until 8/31/2014. Exclusion Criteria: * Patients who through chart review were found to have been primarily suffering from delirium from causes other than AWS.

What they're measuring

Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score

Timeframe: Baseline to month 6

Trial details

NCT IDNCT05438641

SponsorStanford University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-08

View on ClinicalTrials.gov More Alcohol Withdrawal Syndrome trials